Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
| ▸ | BCL9 | O00512 | 15/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 15/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24873112 | 0.86 | BCL9 (0.46) | NR1H2NR1H3BCL9CTNNB1GPR119 | |
| SCHEMBL30609810 | 0.86 | BCL9 (0.46) | NR1H2NR1H3BCL9CTNNB1GPR119 | |
| SCHEMBL24873121 | 0.85 | ALDH1A1 (0.44) | BCL9CTNNB1GPR119NOTUM | |
| SCHEMBL31258386 | 0.85 | NOTUM (0.59) | BCL9CTNNB1NOTUM | |
| SCHEMBL23124821 | 0.85 | NOTUM (0.59) | BCL9CTNNB1NOTUM | |
| SCHEMBL23124851 | 0.85 | NOTUM (0.59) | BCL9CTNNB1NOTUM | |
| SCHEMBL31258377 | 0.83 | BCL9 (0.49) | BCL9CTNNB1NOTUM | |
| SCHEMBL30609813 | 0.82 | MAP4K4 (0.47) | BCL9CTNNB1 | |
| SCHEMBL30093635 | 0.81 | BCL9 (0.50) | BCL9CTNNB1 | |
| SCHEMBL30361577 | 0.81 | BCL9 (0.50) | BCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | Nantong Jutai Biotech Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | BCL9, BCL9L, BCL2L11 | NR1H2 426/4885NR1H3 313/4885BCL9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.